Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03937635	Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma	recruiting	Phase 3	288	ECOG-ACRIN Cancer Research GroupNETWORK	2	Aug 19, 2026	clinicaltrials

Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials